Get started
Author

Martha E. Anderson

Observed names: M Anderson, M. Anderson, Martha Anderson, Martha E Anderson
ORCID: 0009-0006-5235-1904
Observed ORCID: 0009-0006-5235-1904
OpenAlex ID: A5046639473
Reducing hydrophobicity of homogeneous antibody-drug conjugates improves pharmacokinetics and therapeutic index
2015 · Robert P Lyon, Tim D Bovee, et al. · Nature Biotechnology · 579
Self-hydrolyzing maleimides improve the stability and pharmacological properties of antibody-drug conjugates
2014 · Robert P Lyon, Jocelyn R Setter, et al. · Nature Biotechnology · 479
CD133/prominin-1 is a potential therapeutic target for antibody-drug conjugates in hepatocellular and gastric cancers
2008 · L M Smith, A Nesterova, et al. · British Journal of Cancer · 289
PDF
A Potent Anti-CD70 Antibody–Drug Conjugate Combining a Dimeric Pyrrolobenzodiazepine Drug with Site-Specific Conjugation Technology
2013 · Scott C. Jeffrey, Patrick J. Burke, et al. · Bioconjugate Chemistry · 247
Development of orally active inhibitors of protein and cellular fucosylation
2013 · Nicole M. Okeley, Stephen C. Alley, et al. · Proceedings of the National Academy of Sciences · 189
Novel Peptide Linkers for Highly Potent Antibody−Auristatin Conjugate
2008 · Svetlana O. Doronina, Tim D. Bovee, et al. · Bioconjugate Chemistry · 182
Optimization of a PEGylated Glucuronide-Monomethylauristatin E Linker for Antibody–Drug Conjugates
2016 · Patrick J. Burke, Joseph Z. Hamilton, et al. · Molecular Cancer Therapeutics · 159
The Pharmacologic Basis for Antibody-Auristatin Conjugate Activity
2009 · Stephen C. Alley, Xinqun Zhang, et al. · Journal of Pharmacology and Experimental Therapeutics · 135
SGN–LIV1A: A Novel Antibody–Drug Conjugate Targeting LIV-1 for the Treatment of Metastatic Breast Cancer
2014 · Django Sussman, Leia M. Smith, et al. · Molecular Cancer Therapeutics · 130
Design, Synthesis, and Biological Evaluation of Antibody−Drug Conjugates Comprised of Potent Camptothecin Analogues
2009 · Patrick J. Burke, Peter D. Senter, et al. · Bioconjugate Chemistry · 116
Characterization of SGN-CD123A, A Potent CD123-Directed Antibody–Drug Conjugate for Acute Myeloid Leukemia
2017 · Fu Li, May Kung Sutherland, et al. · Molecular Cancer Therapeutics · 106
Engineered anti-CD70 antibody-drug conjugate with increased therapeutic index
2008 · Charlotte F. McDonagh, Kristine M. Kim, et al. · Molecular Cancer Therapeutics · 96
Targeting pancreatic and ovarian carcinomas using the auristatin-based anti-CD70 antibody–drug conjugate SGN-75
2010 · M C Ryan, H Kostner, et al. · British Journal of Cancer · 88
Brentuximab Vedotin–Driven Microtubule Disruption Results in Endoplasmic Reticulum Stress Leading to Immunogenic Cell Death and Antitumor Immunity
2023 · Ryan A. Heiser, Anthony T. Cao, et al. · Molecular Cancer Therapeutics · 70
PDF
Engineered cysteine antibodies: an improved antibody-drug conjugate platform with a novel mechanism of drug-linker stability
2018 · D Sussman, L Westendorf, et al. · Protein Engineering Design and Selection · 56
Targeted Delivery of Cytotoxic NAMPT Inhibitors Using Antibody–Drug Conjugates
2018 · Christopher S. Neumann, Kathleen C. Olivas, et al. · Molecular Cancer Therapeutics · 53
An in Vitro Assay Using Cultured Kupffer Cells Can Predict the Impact of Drug Conjugation on in Vivo Antibody Pharmacokinetics
2020 · David W Meyer, Lauren B Bou, et al. · Molecular Pharmaceutics · 35
5-Azacytidine enhances the anti-leukemic activity of lintuzumab (SGN-33) in preclinical models of acute myeloid leukemia
2010 · May Kung Sutherland, Changpu Yu, et al. · mAbs · 29
PDF
Novel immunoconjugates comprised of streptonigrin and 17-amino-geldanamycin attached via a dipeptide-p-aminobenzyl-amine linker system
2009 · Patrick J. Burke, Brian E. Toki, et al. · Bioorganic & Medicinal Chemistry Letters · 25
SGN-CD123A, a Pyrrolobenzodiazepine Dimer Linked Anti-CD123 Antibody Drug Conjugate, Demonstrates Effective Anti-Leukemic Activity in Multiple Preclinical Models of AML
2015 · May S.K. Sutherland, Changpu Yu, et al. · Blood · 22
Abstract 1195: SGN-CD352A: A novel humanized anti-CD352 antibody-drug conjugate for the treatment of multiple myeloma
2016 · Tim Lewis, Devra J. Olson, et al. · Cancer Research · 18
Improving Antibody‐Tubulysin Conjugates through Linker Chemistry and Site‐Specific Conjugation
2020 · Joseph Z. Hamilton, Thomas A. Pires, et al. · ChemMedChem · 17
PDF
Abstract 2647: SGN-CD70A, a novel and highly potent anti-CD70 ADC, induces double-strand DNA breaks and is active in models of MDR+ renal cell carcinoma (RCC) and non-Hodgkin lymphoma (NHL)
2014 · Sharsti Sandall, Martha Anderson, et al. · Cancer Research · 11
SGN-CD33A in Combination with Hypomethylating Agents Is Highly Efficacious in Preclinical Models of AML
2015 · May S.K. Sutherland, Changpu Yu, et al. · Blood · 10
Feasibility of bevacizumab (NSC 704865, BB-IND# 7921) combined with vincristine, topotecan, and cyclophosphamide in patients with first recurrent Ewing sarcoma (EWS): A Children's Oncology Group (COG) study.
2010 · P. Leavey, J. L. Glade Bender, et al. · Journal of Clinical Oncology · 9
Works count: 91
Citation count: 3,216
H-index: 20
I10-index: 24
Year
Topic
Type